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HIGHLIGHTS
A surface modification protocol
for MOFs compatible with cargo
loading is reported
PEGylated UiO-66 nanoparticles
show pH-responsive cargo
release
Endocytosis routes are modified
by the control of MOF surface
chemistry
Enhanced cytotoxicity is observed
for PEGylated UiO-66 loaded with
dichloroacetatePorous nanoparticles that can store drug molecules have great potential in drug
delivery, the use of nanocarriers to transport therapeutic agents around the body.
Forgan and colleagues report on amethod that controls the surface properties and
functionality of metal-organic framework nanoparticles to enhance their stability,
allow stimuli-responsive release of drug molecules, and enhance the anticancer
therapeutic effect of loaded drugs by changing the route of cell uptake. Further
development of these materials could enhance drug efficiencies and avoid
unwanted side effects.Aba´nades La´zaro et al., Chem 2, 561–578
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Using artificial agents to deliver
drugs selectively to sites of
disease while protecting them
from metabolism and clearance
offers potential routes to new
treatments. Porous metal-organic
frameworks (MOFs) have
emerged as potential candidates
because they offer high storage
capacities and easy clearance
after delivery. We report on a
method that controls the size and
surface chemistry of MOFs and is
compatible with cargo loading,
showing that surface modification
with biocompatible poly(ethylene
glycol) chains improves stability
toward phosphate and allows pH-SUMMARY
The high storage capacities and excellent biocompatibilities of metal-organic
frameworks (MOFs) have made them emerging candidates as drug-delivery vec-
tors. Incorporation of surface functionality is a route to enhanced properties,
and here we report on a surface-modification procedure—click modulation—
that controls their size and surface chemistry. The zirconium terephthalate
MOF UiO-66 is (1) synthesized as 200 nm nanoparticles coated with function-
alized modulators, (2) loaded with cargo, and (3) covalently surface modified
with poly(ethylene glycol) (PEG) chains through mild bioconjugate reactions.
At pH 7.4, the PEG chains endow the MOF with enhanced stability toward phos-
phates and overcome the ‘‘burst release’’ phenomenon by blocking interaction
with the exterior of the nanoparticles, whereas at pH 5.5, stimuli-responsive
drug release is achieved. The mode of cellular internalization is also tuned by
nanoparticle surface chemistry, such that PEGylated UiO-66 potentially escapes
lysosomal degradation through enhanced caveolae-mediated uptake. This
makes it a highly promising vector, as demonstrated for dichloroacetic-acid-
loaded materials, which exhibit enhanced cytotoxicity. The versatility of the
click modulation protocol will allow a wide range of MOFs to be easily surface
functionalized for a number of applications.responsive cargo release, which
could enhance selectivity because
cancerous cells are typically more
acidic than healthy ones. Modes
of cellular uptake are also altered,
which could account for the
enhanced cell death when
polymer-coated MOFs are loaded
with the anticancer drug
dichloroacetic acid. Surface
modification is mild and could be
applied across a range of MOFs,
opening up applications in
selective molecular separation,
blending into hybrids, and turn-on
catalysis.INTRODUCTION
Effective cancer therapy is one of the most challenging goals for the scientific com-
munity because of the lack of tumor selectivity of most therapeutics, which can lead
to toxic dose dependence, serious hepatic problems, and diverse side effects.1–3
Thus, drug-delivery systems have become one of the most promising applications
for health care.4–6 A large number of strategies have been studied, but for applica-
tion, drug-delivery systems must overcome issues surrounding bioavailability,7,8
the uncontrollable release of drugs (usually due to carrier instability),9–11 loading
capacities,11–13 particle size,14–16 nanoparticle cellular internalization routes,14,17,18
and toxicity.19,20 The exceptional storage capacities of metal-organic frameworks
(MOFs), together with their robustness and structural tailorability, have made
them attractive for a wide variety of applications,21,22 including several promising
breakthroughs in biomedicine.9,10,23–33 One of their main advantages is that their
cytotoxicity and properties can be tuned by the thoughtful choice of metal and
linkers.20,34,35
Surface modifications of drug nanocarriers are of high importance because the
carrier stability, drug-release kinetics, and particle cellular internalization can beChem 2, 561–578, April 13, 2017 ª 2017 The Author(s). Published by Elsevier Inc.
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Figure 1. Click Modulation of UiO-66 MOFs
(A) Schematic of the ‘‘click modulation’’ protocol, where functionalized modulators are (i)
incorporated onto MOF surfaces during synthesis and (ii) selectively chemically modified.
(B) The structure of UiO-66, which has been functionalized by click modulation.
(C) The ligand, bdc, and modulators (L1 and L2) applied in this study.
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http://dx.doi.org/10.1016/j.chempr.2017.02.005tuned.9,18 Particle characteristics such as size, shape, and surface chemistry play
key roles in determining the cellular-uptake pathways.36–38 Although a consider-
able amount of work has been performed to modify the bulk structure and internal
pore spaces of MOFs,39–42 only a few studies have addressed their external surface
chemistry, usually through surface-selective postsynthetic modification protocols
designed for specific MOFs and surface substrates.9,24,43–48 For example, coatings
with different polymers have decreased immune system recognition and accumu-
lation in the liver for nanoparticulate MOFs (NMOFs) and have shown promising
in vitro and in vivo results in anticancer therapy.9,24 In addition, they can be tar-
geted to cancer cells by the attachment of different targeting units to their surface
through postsynthetic modifications, avoiding non-specific distribution of the
drug.49,50
The size and shape of NMOF particles can be tuned by the introduction of modula-
tors—monotopic capping agents such as benzoic acid—to their syntheses.51–55
Coordination modulation offers the prospect of decorating the external surfaces
of NMOFs with desirable functionality during the synthetic process, but this remains
a challenge.56,57 Herein, we present a reproducible two-stepmethod, which we have
termed ‘‘click modulation,’’ for the general surface modification of zirconium-based
NMOFs (Figure 1A). This method introduces functionalized modulators to the
NMOFs’ external surfaces during the synthetic process to control particle size
and subsequently transforms them in further postsynthetic modifications by using
high-yielding ‘‘click’’ chemistry compatible with cargo-loaded NMOFs.
Incorporation of polymers onto the external surfaces of NMOFs has been suggested
as a route to enhanced stability and effective application in drug delivery.58 We have
therefore used our click modulation protocol to covalently attach poly(ethylene
glycol) (PEG) chains to the NMOFs’ surfaces to improve their stability and drug-
release kinetics and also facilitate pH-responsive release of cargo. The effect of562 Chem 2, 561–578, April 13, 2017
postsynthetic surface modification on cancer cell endocytosis pathways was also
studied,14,38 revealing that cellular internalization routes of NMOFs can be medi-
ated by their surface chemistry.RESULTS AND DISCUSSION
The zirconium MOF UiO-66 (UiO stands for Universitetet i Oslo; Figure 1B)59 is
biocompatible and has a half maximal inhibitory concentration (IC50) of 1.50 G
0.15 mg/mL against the HeLa cell line after 24 hr of exposure.60 Its idealized struc-
ture, Zr6O4(OH)4(bdc)6, where bdc stands for 1,4-benzenedicarboxylate, has
been well characterized and possesses a remarkable thermal and chemical sta-
bility in comparison with that of other MOFs.59,61,62 UiO-66 is also known to
incorporate synthetic modulators at surface and defect sites63–65 and so was
chosen for study. p-Azidomethylbenzoic acid (L1) and p-propargyloxybenzoic
acid (L2) were selected as click modulators (Figure 1C) for UiO-66 synthesis
because of their structural similarities to the bdc linker and the fact that, if attached
to the Zr6 clusters, the desired functionalities should point outward,
46 resulting in
accessible reactive groups as platforms for further postsynthetic modifications on
its surface.Synthesis and Characterization of UiO-66-L1 and UiO-66-L2
UiO-66 nanoparticles were synthesized under solvothermal conditions (Supple-
mental Information, Section S2) by the addition of 1, 3, or 5 equiv of the desired
modulator (L1 or L2) and acetic acid (AcOH) as the co-modulator. Full characteriza-
tion (Supplemental Information, Section S3) showed that the particles were highly
crystalline, as confirmed by powder X-ray diffraction (PXRD) (Figure S1), and nuclear
magnetic resonance (NMR) spectroscopy of acid-digested samples showed that
modulator incorporation increased with the number of equivalents of modulator
added to the reaction mixture (Figures S2 and S3); the estimated maximum content
was 13.3 mol % of L1 (5 equiv added) in comparison with bdc and 17.1 mol % of L2
(5 equiv added). Infrared (IR) spectroscopy revealed an increase in the intensity of the
azide vibration band at 2,100 cm1 as the number of equivalents of L1 in UiO-66-L1
syntheses increased, whereas vibration bands characteristic of ChC triple bonds
were observed for UiO-66-L2 (Figure S4). Because of these encouraging results,
all subsequent syntheses utilized 5 equiv of the corresponding modulator and 7%
v/v of AcOH, and these samples are designated UiO-66-L1 and UiO-66-L2. A
comparison sample, UiO-66-AcOH, was prepared in a synthesis modulated only
by 7% v/v AcOH.
Quantifying modulator incorporation by thermogravimetric analysis (TGA) is diffi-
cult; compared with UiO-66-AcOH, modulated samples did not lose extra mass,
indicating that the modulators, which are chemically similar to the bdc linkers and
whose presence was confirmed by 1H NMR spectroscopy, decompose at similar
temperature (Figure S8). This suggests that L1 and L2 are attached to the external
surface and at defect sites of the MOF and not simply loaded in the pores. UiO-66
has been reported to be highly porous; if defect free, its Brunauer-Emmet-Teller
(BET) surface area is around 1,200 m2 g1, and its pore volume is 0.5 cm2 g1.59
To characterize the porosity of UiO-66-L1 and UiO-66-L2, we collected N2 adsorp-
tion isotherms at 77 K (Figure S9). The modulated samples exhibited higher surface
areas (SBET = 1,565 m
2 g1 for UiO-66-L1 and 1,420 m2 g1 for UiO-66-L2),
again suggesting that modulator incorporation induces defects rather than simply
occupying and blocking pores,57 and the pore-size distributions of the modulated
samples were similar to those reported for UiO-66 (8 and 11 A˚).59Chem 2, 561–578, April 13, 2017 563
Figure 2. Proof-of-Concept Surface Modification of UiO-66 with Alkanes
(A) Schematic of the click modulation protocol in the preparation of UiO-66-L1-dodecane.
(B) Stacked IR spectra showing the disappearance of the azide stretch and appearance of C–H
signals after the CuAAC surface reaction has taken place on UiO-66-L1.
(C) Stacked PXRD profiles of UiO-66-L1 and UiO-66-L2 before and after alkylation.
(D) N2 adsorption isotherms (77 K) of the MOFs show a decrease in gravimetric uptake as additional
mass is incorporated onto their surfaces. Closed symbols represent adsorption, and empty symbols
represent desorption.Proof-of-Concept Surface Functionalization
After confirming that the functionalized modulators were incorporated into the MOF
structure, we attempted postsynthetic modification by copper(I)-catalyzed azide-
alkyne cycloaddition (CuAAC)66 (Supplemental Information, Section S4). Various
catalysts were tested, including CuI and a mixture of CuSO4 and sodium ascorbate,
resulting in loss of the sample crystallinity each time. An efficient and economic
approach, using CuI and 2 equiv of both acetic acid and N,N-diisopropylethylamine
as an in situ stabilizing ligand for Cu(I),67 was tolerated by the MOF structure, as
confirmed by PXRD (Figure S10), and allowed further functionalization of the
NMOFs.
Proof-of-concept reactions using this catalyst were carried out between UiO-66-L1
and 1-dodecyne (Figure 2A), as well as between UiO-66-L2 and 1-azidodecane.
1H NMR spectra of acid-digested samples of UiO-66-L1-dodecane and UiO-66-L2-
decane suggested significant conversions of the modulators into the respective
triazole products; although the low modulator content makes analysis difficult,
additional aromatic signals are present alongside peaks for the alkyl groups. Full
conversion would not be expected, given that some modulators will be located at
inaccessible internal defect sites rather than on the particle surface.
Fourier transform IR (FT-IR) spectra also showed the disappearance of signals
for modulator azide and alkyne groups and the appearance of triazole bands and
surface functionality, which compared well with spectra of authentic samples of564 Chem 2, 561–578, April 13, 2017
‘‘clicked’’ modulators prepared separately in solution-phase reactions (Figure 2B),
whereas high-resolution electrospray ionization mass spectrometry (HR-ESI-MS)
of acid digests of the modified MOFs confirmed the presence of the triazole prod-
ucts. The crystallinity, as measured by PXRD (Figure 2C), and porosity (Figure 2D)
of the samples after functionalization with alkyl chains were both maintained, such
that surface areas were slightly lower (1,168 m2 g1 for UiO-66-L1-dodecane and
1,262 m2 g1 for UiO-66-L2-decane) that those of their precursors, UiO-66-L1
(1,565 m2 g1) and UiO-66-L2 (1,420 m2 g1). Surface functionalization with alkyl
chains increases the mass of the particles, and so a decrease in gravimetric surface
area is expected.68 These decreases correlate well with the new mass-loss features
observed in TGA profiles of UiO-66-L1-dodecane and UiO-66-L2-decane (10.1%
and 10.0% w/w, respectively), which correspond to decomposition of the surface
alkyl chains of the functionalized materials (Figures S12 and S13).
Scanning electron microscopy (SEM) showed that UiO-66-L1 forms well-defined
nanoparticles around 100–200 nm in size (Figure S6) in a manner similar to a recently
reported modulated synthesis of a related zirconium fumarate MOF.69,70 In contrast,
UiO-66-L2 has a larger particle size, around 400–600 nm (Figure S7), suggesting that
click modulation can be used to control nanoparticle size as well as surface chemis-
try. Because the UiO-66-L1 nanoparticles have the appropriate size for drug-delivery
applications,16 we decided to continue our research toward surface functionalization
of UiO-66-L1 for drug delivery. Specifically, PEG chains were chosen because they
present an amphiphilic behavior that resembles that of human cellular mem-
branes,71 whereby the flexible and rapidly changing structure of the PEG hinders
the immune system in the modeling of antibodies around it.72
The monomethyl ethers of PEG550 (average Mn = 550) and PEG2000 (average
Mn = 2,000) were alkylated with propargyl units and used for conjugation with the
azide-functionalized UiO-66-L1 under the previously determined Cu(I)-catalyzed
conditions (Supplemental Information, Section S4). Full 1H NMR spectroscopic anal-
ysis of the acid-digested products, UiO-66-L1-PEG550 and UiO-66-L1-PEG2000,
is difficult because of the intensity of the polymer signals. However, a control
experiment—stirring PEG2000-propargyl or PEG550-propargyl with UiO-66-L1
but without catalyst—revealed that, without Cu(I) catalyst, no polymer was present
in the sample at all, confirming that covalent linkage is required for the PEG to
remain attached to the MOF.
TGA profiles of UiO-66-L1-PEG550 and UiO-66-L1-PEG2000 (Figure 3A) showed ex-
tra mass losses (21.7% and 23.1% w/w, respectively) at temperatures corresponding
to those reported for PEG in the literature,73 whereas no extra mass losses were
found in the control samples. HR-ESI-MS of digested UiO-66-L1-PEG550 (Figure 3B)
confirmed that the click reaction between UiO-66-L1 and PEG550-propargyl had
taken place, and although derivatives of the larger PEG2000 species did not ionize
under the available conditions, functional-group conversion was observed by IR
spectroscopy (Figure S16).
PXRD confirmed that the PEGylated NMOFs retained their crystallinity (Figure S17),
and a decrease in their N2 uptake was observed; the incorporated mass of the PEG
chains led to BET surface areas of 865 m2 g1 for UiO-66-L1-PEG550 and 521m2 g1
for UiO-66-L1-PEG2000 (Figure 3C). The pore-size distribution of UiO-66-L1-
PEG550 corresponds with that reported for UiO-66, but in the case of UiO-66-L1-
PEG2000, the adsorption and desorption isotherms reveal a type IV isotherm, typical
of mesoporous materials, but with no closure point. In the case of nitrogenChem 2, 561–578, April 13, 2017 565
Figure 3. Surface Modification of UiO-66 with Poly(ethylene glycol)
(A) TGA profiles of UiO-66-L1-PEG550 and UiO-66-L1-PEG2000 are compared with those of control samples of UiO-66-L1 that had been exposed to
propargyl-functionalized PEGs without any Cu(I) catalyst.
(B) HR-ESI-MS of digested UiO-66-L1-PEG550 confirms that the CuAAC reaction took place between the MOF and the PEG chain.
(C) N2 uptake isotherms (77 K) of the PEGylated MOFs. Closed symbols represent adsorption, and empty symbols represent desorption.
(D) SEM images of UiO-66-L1 particles with differing surface functionality show the morphological changes as larger surface units are incorporated by
click modulation. The scale bar (200 nm) applies to all images.adsorption at 77 K, the lower closure point is usually located around p/p0 0.42, and
any hysteresis recorded below this point has been attributed to irreversible changes
such as swelling of the adsorbent or surface impurities.74 A similar phenomenon was
found by Wang et al.43 on UiO-66 functionalization with the phospholipid dihydrox-
yphenylalanine (DOPA), although to a lesser degree. The fact that PEG2000 chains
are considerably bigger in size than DOPA could explain why it is more pronounced
in this case.
Interestingly, the physical effects on nanoparticle morphology can be observed by
SEM imaging (Figure 3D). As the chain length of the surface functionality increases,
the particles become more rounded in shape with less-defined edges and vertices,
because their surface features become dominated by the bulk of their capping
polymers rather than the underlying MOF crystal structure. Image analysis (Figures
S18–S20) also showed a gradual increase in particle size from 146.6 G 29.3 nm for
UiO-66-L1 to 160.2 G 26.9 nm for UiO-66-L1-PEG550 and 172.9 G 36.8 nm for
UiO-66-L1-PEG2000, consistent with the addition of surface polymer chains of
increasing size.
Solution stability and aggregation were investigated by dynamic light scattering
(DLS). Measurements in methanol (0.25 mg/mL; Figure S21) showed stable disper-
sions of PEGylated particles at sizes around 150 nm, correlating well with the
SEM data70 and confirming that no aggregation takes place; in contrast, the unfunc-
tionalized materials UiO-66-AcOH (800 nm) and UiO-66-L1 (300 nm) showed
aggregation. The power of the surface functionalization protocol was further
demonstrated by DLS measurements in aqueous media (Figures S22 and S23).
UiO-66-L1 was observed to sediment and precipitate from 0.25 mg/mL aqueous566 Chem 2, 561–578, April 13, 2017
dispersions over time, with aggregates around 2,000–3,000 nm. UiO-66-L1-PEG550
aggregated to a lesser extent, with stable assemblies around 1,000–1,500 nm, but
the larger PEG chains of UiO-66-L1-PEG2000 conferred further dispersive stability,
such that assemblies around 250 nm were observed to aggregate to around
400 nm during the experiments. The dependence of aggregation on PEG chain
size clearly demonstrates the stabilizing effects of surface modification and the
advantages of MOF PEGylation for drug delivery.
In addition, the cytotoxicities of UiO-66-L1-PEG550 and UiO-66-L1-PEG2000, as
well as modulators L1 and L2, were assessed by the bioreduction of a tetrazolium
compound (MTS), known as the MTS assay (Figures S24 and S25). None of the ma-
terials showed any toxicity toward HeLa cells at concentrations up to 1 mg/mL.
The successful covalent surface modification of UiO-66 with both alkyl and PEG
chains confirms the versatility and general applicability of the click modulation pro-
cess. PEG chains have previously been incorporated onto silica-coated UiO-66(Hf),
and although this approach facilitated in vivo imaging by computed tomography,75
it might not be suitable for drug delivery because the silica coating can block access
to the pores of the MOF and could affect clearance.
Degradation Kinetics of PEGylated and Uncoated UiO-66-L1
To be an efficient injectable treatment, the nanocarrier should be stable at the first
stages of the treatment; ideally, it should not be degraded in extracellular conditions
(i.e., blood [pH 7.4]) in order to avoid renal clearance of the drug yet not be persis-
tent enough to be accumulated over longer treatment periods. The nature of the
metal-linker coordination bonds in MOFs ensures total degradation of the structure
at sufficiently acidic pH ranges as a result of linker protonation,76 but strongly coor-
dinating molecules, such as phosphates, are also able to displace the linkers in the
structure at extracellular pH.24 Although the rapid degradation of MOFs under
physiological conditions ensures no accumulation of the carrier after it has reached
its target and released the drug,10,77 their instability toward phosphates, which are
present in the blood, typically hinders NMOF bioapplications because of
fast-release kinetics,77 and several approaches, such as amorphisation60 or silica
coating,29,39,75,78 among others, have been studied for improving their stability to
phosphate.
The stabilities of UiO-66-L1, UiO-66-L1-PEG550, and UiO-66-L1-PEG2000 were
determined in phosphate buffered saline (PBS) at pH 7.4 (Supplemental Information,
Section S5) via measurement of the release of bdc linkers by UV-Vis spectroscopy
(Figure 4A). L1 was found to have a UV-Vis absorbance profile and extinction coef-
ficient similar to those of bdc and so does not significantly affect the measurements.
UiO-66-L1 exhibited an exponential degradation profile reaching a plateau around
85% bdc release after 6 hr of exposure. On the other hand, PEGylated samples ex-
hibited sigmoidal degradation profiles. We observed that the PEG-modified
NMOFs degraded at much slower rates during the first 2 hr, after which they reached
plateaus similar to those of the uncoated samples at the end of the experiment (Fig-
ures S26–S30).
PXRD analysis (Figure 4B) also showed that crystallinity is retained for longer when
the samples have been PEGylated, particularly in the first few hours. We expect
that the surface corona of covalently attached PEG chains hinders phosphate attack
of the Zr6 clusters of the UiO-66 samples, given that the phosphate groups must first
diffuse through the PEG coating to reach the zirconium positions, displace theChem 2, 561–578, April 13, 2017 567
Figure 4. Enhanced Stability of PEGylated UiO-66
(A) Degradation profiles of UiO-66-L1, UiO-66-L1-PEG550, and UiO-66-L1-PEG2000 in PBS (pH 7.4).
Error bars denote standard deviations from triplicate experiments.
(B) PXRD profiles of the MOFs after immersion in PBS for differing times show the improved stability
of the PEGylated MOFs.modulators and linkers, and coordinate to the zirconium ions similarly to the un-
coated NMOF. This enhanced stability means that the burst effect, due to carrier
degradation,79 could be avoided at the first stages of the treatment, improving
the treatment efficiency and reducing undesirable side effects while ensuring that
the framework can degrade, release cargo, and be cleared over larger periods of
exposure.
Synthesis, Functionalization, and Characterization of Calcein-Containing
NMOFs
In order to determine the effect of the PEGylation upon drug-release kinetics and
cell internalization routes, we chose calcein as a model drug because of its structural
similarities to doxorubicin.2,60 Calcein is hydrophilic and does not permeate the cell
membrane; rather, it requires a drug-delivery vehicle to facilitate its entry into cells.
In addition, like doxorubicin, it is a fluorescent molecule, and because of its self-
quenching character it can be detected only when it is released from the delivery
vector, allowing the measurement of cytoplasmic fluorescence by confocal micro-
scopy or flow cytometry.80 The versatility of the click modulation technique is further
demonstrated by its compatibility with cargo loading (Supplemental Information,
Section S6). Simply stirring azide-modified UiO-66-L1 in a concentrated methanolic
calcein solution resulted in higher incorporation of calcein (16.0% w/w as deter-
mined by UV-Vis spectroscopy) than previously reported in the literature for UiO-
66, most likely as a result of the increased porosity of UiO-66-L1.60 We named the
calcein-loaded sample cal@UiO-66-L1. The functionalized modulator L1 remained
attached to the MOF framework after calcein uptake, as determined by 1H NMR
spectra of the digested samples, and the azide functionality was used once again
to incorporate PEG chains of different lengths according to the CuAAC protocol.
Crystallinity was preserved after calcein loading (Figure S32) and PEGylation, and
their size, analyzed by SEM, was found not to change (Figure S33). Calcein content
was analyzed by UV-Vis spectroscopy and found to be 13.3% w/w for cal@UiO-66-
L1-PEG550 and 10.3% w/w for cal@UiO-66-L1-PEG2000 (Figure S34). This confirms
that click modulation is compatible with cargo loading, and the decreasing
loading values are commensurate with the increasing mass of the particles after
PEGylation.
Confirmation of calcein loading by TGA analysis was complicated by the absence
of the first calcein thermal decomposition step in the loaded MOF samples568 Chem 2, 561–578, April 13, 2017
Figure 5. pH-Responsive Release of Calcein from PEGylated UiO-66
(A) Calcein-release profiles from UiO-66-L1, UiO-66-L1-PEG550, and UiO-66-L1-PEG2000 in PBS
(pH 7.4 and 5.5).
(B) pH-responsive release of calcein from the PEGylated MOFs. Inset: chemical structure of calcein.
Error bars denote standard deviations from triplicate experiments.(Figure S35), indicating that calcein is attached to the external surface and at defect
sites. Calcein decomposition occurred over a temperature range similar to that
observed previously for PEG groups, making exact quantification troublesome
but confirming the presence of the surface PEG functionality in cal@UiO-66-
L1-PEG550 and cal@UiO-66-L1-PEG2000 (Figure S36). N2 adsorption isotherms
(77 K) confirmed that cal@UiO-66-L1 exhibited a decrease in surface area (SBET =
1,002 m2 g1) but maintained the pore-size distribution characteristic of UiO-66,
again suggesting that calcein is not significantly blocking the pores but attaching
to the particle surface and localizing at defects (Figure S37). The porosity of both
PEGylated calcein-loaded samples (SBET = 826 m
2 g1 for cal@UiO-66-L1-PEG550
and SBET = 683 m
2 g1 for cal@UiO-66-L1-PEG2000) decreased similarly to that of
the empty PEGylated UiO-66-L1 samples, confirming PEG surface attachment can
occur without displacing molecular cargo.
pH-Dependent Calcein-Release Profiles
The effect of surface modification on calcein release was monitored in PBS
at pH 7.4 and 5.5 according to a UV-Vis spectrophotometric analysis protocol
similar to the degradation experiments (Supplemental Information, Section S7).
Monitoring release at different pH values is very important given that extracellular
pH is 7.4, intracellular pH is 6.8, and the pH of cancer cells is close to 5.5,81
providing a potential mechanism for targeted drug delivery. The release of
calcein from both coated and uncoated samples was affected by the pH (Figure 5A);
however, the release at pH 7.4 was drastically decreased for the PEGylated
samples. Both cal@UiO-66-L1-PEG550 and cal@UiO-66-L1-PEG2000 initially
released calcein slowly at pH 7.4 and did not release more than 30% of their total
cargo after 5 days. In contrast, they rapidly released 80% of cargo within an
hour at pH 5.5 and released nearly the full amount in pH 5.5 after 2 days (Figures
S38–S50).
If this behavior can be retained in vivo, PEGylated UiO-66 samples could be ex-
pected to store the majority of cargo in extracellular conditions and thus avoid the
non-selective distribution of therapeutics while being able to release it once it has
reached its target. The stimuli-responsive release of calcein from the PEGylated
MOFs was therefore assessed by a similar experiment, where the pH of the PBS so-
lution was adjusted from 7.4 to 5.5 after 5 days (Figure 5B). An immediate, rapid
release of calcein was observed, whereby slightly less calcein was released fromChem 2, 561–578, April 13, 2017 569
UiO-66-L1-PEG2000 than from the analog with the shorter chain. Nonetheless, this
result is highly promising for drug-delivery applications should the particles be
efficiently internalized by cells.
To gain further insight into the mechanism of release, we subjected samples of the
MOFs to simulated release conditions at pH 7.4: cal@UiO-66-L1 after 1 day and
cal@UiO-66-L1-PEG2000 after 2 days (Supplemental Information, Section S8).
The amount of calcein released from both individual experiments determined by
UV-Vis spectroscopy (67.5% from cal@UiO-66-L1 and 42.7% from cal@UiO-66-L1-
PEG2000) is in concordance with the release profiles. Both samples showed a
decrease in crystallinity by PXRD after calcein release, although the characteristic
UiO-66 reflection peaks could be determined (Figure S51), meaning that the core
of the materials remained crystalline. TGA showed the disappearance of the PEG
moiety from cal@UiO-66-L1-PEG2000 and an increase on the metal residue for
both samples (Figure S52), suggesting some degradation. Both samples remained
porous (Figure S53); the surface area of cal@UiO-66-L1 (SBET = 1,155 m
2 g1)
increased from the release of significant amounts of calcein mass, and the surface
area of cal@UiO-66-L1-PEG2000 (SBET = 554 m
2 g1) decreased slightly, possibly
because of pore blocking or the incorporation of additional mass, such as
phosphates.
We hypothesize that, at pH 7.4, the phosphates present in PBS attack the zirconium
positions24 and displace the surface ligands and the calcein. When UiO-66 is not
PEGylated, the MOF is much more accessible (both internally and externally) and
therefore so are the zirconium clusters, enabling a faster exchange between phos-
phates and ligands, modulators, and calcein. On the other hand, for surface-modi-
fied cal@UiO-66-L1-PEG2000, the phosphates must diffuse through the PEG
coating before reaching the MOF. We hypothesize that a corona of coordinating
phosphates is then formed, obstructing the MOF and hindering further phosphate
attack to release remaining calcein molecules. Indeed, FT-IR spectra of cal@UiO-
66-L1-PEG2000 after 1 day in PBS at pH 7.4 showed more significant signals for
phosphates than for cal@UiO-66-L1 under the same conditions (Figure S54),
suggesting that the PEG coating induces a corona build-up and that unmodified
UiO-66 simply undergoes surface exchange (Supplemental Information, Section
S8). When the pH is more acidic, the carboxylate units of bdc ligands, surface func-
tionality, and calcein are easier to protonate, and therefore MOF degradation and
calcein release are much more pronounced.76
Endocytosis Studies
Confocal fluorescence microscopy has been used to confirm successful internaliza-
tion of theMOF nanoparticles by HeLa cells and subsequent calcein release (Supple-
mental Information, Section S9). Figure 6 shows the confocal microscopy images
of HeLa cells incubated with, from top to bottom, nothing (control), free calcein,
cal@UiO-66-L1, cal@UiO-66-L1-PEG550, and cal@UiO-66-L1-PEG2000. We used
Hoechst 33342 (H33342) and CellMask to stain the nucleus and membrane of the
cells, respectively. We used CellMask as a viability control to probe the cell mem-
brane integrity and show that the MOFs were inside the cells. The effectiveness of
calcein as a probe is demonstrated by the fact that free calcein was not taken up
by cells, in concert with previous reports,60,80,82 so any green fluorescence within
cells comes from released calcein from internalized MOF materials. UiO-66-L1,
UiO-66-L1-PEG550, and UiO-66-L1-PEG2000 all transported calcein into HeLa cells,
as seen by the green fluorescence, whereas the control cells and those incubated
with free calcein showed no signal.570 Chem 2, 561–578, April 13, 2017
Figure 6. Confocal Microscopy Images of HeLa Cells Incubated with Different Materials
From top to bottom: control, free calcein, cal@UiO-66-L1, cal@UiO-66-L1-PEG550, and cal@UiO-
66-L1-PEG2000. Cells were subsequently stained with Hoechst 33342 (5 mg/mL) and CellMask
orange (13). Scale bars represent 25 mm in all images except for cal@UiO-66-L1, in which it
represents 10 mm.The transport of calcein into NMOFs allows the study of endocytosis pathways by
fluorescence-activated cell sorting (FACS). There are three main classes of endocy-
tosis pathways: (1) clathrin-mediated, (2) caveolae-mediated, and (3) clathrin- and
caveolae-independent endocytosis such as macropinocytosis.38,83,84 Clathrin-medi-
ated endocytosis involves recognition of the cargo by cell-surface receptors, which
internalize it into protein (clathrin)-coated vesicles 60–200 nm in size, called early en-
dosomes.85 These early endosomes then mature into late endosomes and finally
fuse with lysosomes, causing degradation of the drug-delivery system along with
its loaded cargo, thus nullifying its therapeutic effect.85 On the other hand, caveo-
lae-mediated endocytosis is associated with the formation of lipid-raft-enriched
flask-shaped invaginations (50–100 nm) coated with a protein called caveolin.86 Par-
ticles internalized via caveolae-mediated endocytosis can later be delivered to
different locations in a cell, including a pH-neutral compartment called the caveo-
some, and then transported to a final intracellular location, potentially avoiding lyso-
somal degradation.87,88Chem 2, 561–578, April 13, 2017 571
Figure 7. Effects of Pharmacological Endocytosis Inhibitors on the Uptake of cal@UiO-66-L1,
cal@UiO-66-L1-PEG550, and cal@UiO-66-L1-PEG2000 into HeLa Cells, as Measured by FACS
The statistical significance was determined by ordinary one-way ANOVA and is indicated on the
graph: ***p < 0.001 and ****p < 0.0001.To study the internalization routes of the PEGylated and unPEGylated NMOFs,
we used different pharmacologic inhibitors according to our previous work (Sup-
plemental Information, Section S9).38 First, we used sucrose89 and chlorproma-
zine90 to independently inhibit the clathrin-mediated pathway. Second, we used
nystatin to inhibit the caveolae-mediated pathway.91 Finally, we employed rot-
tlerin92,93 to prevent macropinocytosis. Tracers known to selectively follow each
pathway were used as positive controls for the inhibitors: transferrin and ceramide
for clathrin- and caveolae-mediated pathways, respectively, and dextran for mac-
ropinocytosis. Cells were incubated with each inhibitor for 30 min and then for
90 min together with the NMOF (Supplemental Information, Section S9). Because
nanoparticle size is known to affect cell internalization routes,38 for example, the
recent report of enhanced uptake of 90 nm nanoparticles of a Zr-porphyrin MOF
into HeLa cells,94 we performed all experiments on one base batch of UiO-66-
L1, surface modified and loaded as necessary, to ensure that particle size was rela-
tively homogeneous.
Figure 7 shows the normalized internal fluorescence, obtained through FACS,
of HeLa cells after the uptake of cal@UiO-66-L1, cal@UiO-66-L1-PEG550, and ca-
l@UiO-66-L1-PEG2000 in the presence and absence of the pharmacologic endocy-
tosis inhibitors. The uptake of all three particles at 4C was significantly reduced,
which confirms that they are internalized via an energy-dependent endocytosis pro-
cess. The uptake of cal@UiO-66-L1 after exposure to sucrose and chlorpromazine
was reduced to 27% G 1% and 37% G 5%, respectively, whereas exposure to
nystatin had no effect (107% G 7%), revealing that the unfunctionalized MOF is
not internalized through the caveolae-mediated route. Rottlerin decreased its
uptake to79%G 6%. For cal@UiO-66-L1-PEG550, the uptake after exposure to su-
crose and chlorpromazine decreased to 36% G 2% and 26% G 2%, respectively,
whereas there was no reduction in uptake upon exposure to nystatin (106%G 3%).
Rottlerin slightly decreased the uptake to 89% G 4%. These values are similar to
those for cal@UiO-66-L1, suggesting that the PEG550 coating did not affect the
route of endocytosis.572 Chem 2, 561–578, April 13, 2017
Finally, for cal@UiO-66-L1-PEG2000, exposing the cells to sucrose and chlorproma-
zine decreased the uptake to 28% G 2% and 27% G 2%, respectively. Interest-
ingly, significant changes were found, whereby nystatin and rottlerin reduced the
uptake to 51% G 2% and 45% G 4%, respectively, showing that the PEGylated
MOF is partially internalized through caveolae-mediated endocytosis. This indicates
that the UiO-66 internalization pathway is significantly affected by the functionality
attached to its surface, and the longer PEG chains (Mn  2,000) allow the NMOFs
to partially avoid lysosomal degradation. The amphiphilic nature of cal@UiO-66-
L1-PEG2000, in contrast to the hydrophilic surface of the uncoated sample, is
thought to be more compatible with the caveolae-mediated route. In addition,
part of the cellular trafficking of all three MOFs occurs through macropinocytosis
because the uptake is affected by the presence of rottlerin. However, this is a
non-selective process allowing the internalization of large quantities of material
independently of its constitution.95 Macropinocytosis could be a consequence of
aggregation of nanoparticles if the effects observed by DLS also occur in this
more dilute environment, although it has not been observed as a significant pathway
for the other NMOF samples, which exhibit greater aggregation than UiO-66-L1-
PEG2000.
We used laser confocal microscopy with LysoTracker-Deep red to qualitatively
determine the degree of co-localization between the calcein-loaded NMOF
particles (green) and the lysosomes (Figure S56). After 2 hr of incubation, a high
level of co-localization was found for all three MOFs, given that FACS confirmed
that clathrin-mediated uptake took place in all NMOFs. However, in the case of
cal@UiO-66-L1-PEG2000, a higher degree of localized light-green particles outside
the lysosomes was also observed, suggesting altered uptake mechanisms.
Therapeutic Efficacy of Drug-Loaded NMOFs
To investigate the effect of this alternative uptake mechanism and particle stability
on the therapeutic efficacy of the PEGylated NMOFs, we selected dichloroacetic
acid (DCA) for delivery because it is an anticancer drug that is cytotoxic only once
it is internalized by cells.96 DCA turns on the apoptosis systems of cancer cells, which
is otherwise suppressed, thus allowing them to die.97,98 However, its hydrophilicity
means it is rapidly cleared with a half-life from the first dose of less than 1 hr, and it
can induce neurotoxicity by crossing the blood-brain barrier,99 so DCA is well suited
for use in a nanocarrier system.
DCA was added (Supplemental Information, Section S10) to hydrothermal syntheses
in place of acetic acid to yield DCA@UiO-66-L1. The presence of both DCA and L1
was confirmed by 1H NMR spectroscopy (Figure S57), and the 150 nm particles
observed by SEM were found to be crystalline by PXRD (Figure S58). The material
was PEGylated under the CuAAC conditions used previously to yield DCA@UiO-
66-L1-PEG2000. TGA confirmed the presence of the PEG chain and allowed an esti-
mation of DCA loading; these values were confirmed by inductively coupled plasma
mass spectrometry for measuring the chlorine content, giving DCA loadings of
13.7% w/w for DCA@UiO-66-L1 and 12.1% w/w for DCA@UiO-66-L1-PEG2000 (Fig-
ure S59). The cytotoxicities of the two materials were determined by MTS assay (Fig-
ure 8) against HeLa cells, where it was found that the PEGylatedmaterial induced sig-
nificant cell death at NMOF concentrations of 0.75 mg/mL and above, whereas the
uncoatedmaterial did not. In comparison, DCA alone has been found to have an IC50
of 23.0 G 4.0 mM against methylcholanthrene fibrosarcoma cells, a considerably
higher dose.98 We expect that the enhanced stability and cellular internalization of
the PEGylated MOF contributes significantly to the improved therapeutic effect.Chem 2, 561–578, April 13, 2017 573
Figure 8. Metabolic Activity of HeLa Cells after 72 hr of Exposure to DCA@UiO-66-L1 and
DCA@UiO-66-L1-PEG2000, as Measured by MTS AssayConclusions
We have presented a reproducible and innovative protocol—click modulation—to
selectively introduce surface functionality to the Zr MOF UiO-66. A range of experi-
ments have shown that differing chemical functionality can be incorporated in the
MOF via the CuAAC reaction with functionalized modulators and that the two-stage
process is compatible with cargo loading. Surfacemodification has been shown to be
of prime importance for drug-delivery applications, specifically for UiO-66 nanopar-
ticles loaded with calcein or DCA and coated with PEG chains of different lengths.
PEGylation has been shown to improve the stability of UiO-66 toward phosphate-
induced degradation and dispersion in aqueous media, and calcein release has
been proven to be pH dependent. In contrast to bare nanoparticles, PEGylated
UiO-66 samples did not release more than 40% of their calcein cargo after
5 days at pH 7.4, yet they released the full amount after 2 days in pH 5.5. In addi-
tion, pH-responsive release was achieved in this pH region, mirroring the change
in conditions from blood-stream circulation to cancer cellular internalization to
allow stimuli-responsive drug delivery. The surface chemistry also altered the
cell-uptake routes of the nanoparticles; coating UiO-66 with PEG2000 enhanced
caveolae-mediated endocytosis, allowing the NMOF to partially escape the lyso-
some, thus avoiding degradation of the drug and improving the possibility of
reaching other cellular organelles. This effect was dependent on the length of
the PEG chain; UiO-66 modified with PEG550 did not exhibit similarly enhanced
caveolae-mediated uptake. PEGylation is compatible with loading of the anti-
cancer drug DCA, and compared with DCA@UiO-66-L1, DCA@UiO-66-L1-
PEG2000 exhibits significant cytotoxicity at concentrations above 0.75 mg/mL,
possibly as a consequence of the differing cell-uptake routes, and enhances the
therapeutic effect of DCA.574 Chem 2, 561–578, April 13, 2017
It is clear that functionalizing MOF nanoparticles with polymer chains can
dramatically improve their suitability for biological applications. Our own results
show improved stability, drug release, and cell-uptake properties with biocom-
patible PEG chains, and recent work has shown that polyaniline-modified UiO-
66 is effective and safe for anticancer photothermal therapy.100 We expect the
versatility of the click modulation protocol to allow a variety of MOFs to be
selectively surface functionalized with a variety of chemical units and have imme-
diate application not only in biomedical settings but also in selective adsorption
and separation processes and catalysis. Indeed, during the course of our study,
a similar technique was applied to the functionalization of covalent organic
frameworks.101
EXPERIMENTAL PROCEDURES
Full experimental procedures are provided in the Supplemental Information.
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